Literature DB >> 21232653

Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Adriana Zingone1, W Michael Kuehl.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS), including immunoglobulin light chain only MGUS, is an age-dependent premalignant tumor that is present in about 4% of Caucasian individuals over the age of 50 years. It is comprised of two different kinds of tumors: about 15% lymphoid or lymphoplasmacytoid MGUS and the remainder plasma cell MGUS. Plasma cell MGUS is stable but can sporadically progress to multiple myeloma (MM) at an average rate of about 1% per year. Most, if not all, MM tumors are preceded by plasma cell MGUS, which shares four partially overlapping oncogenic features with MM. It presently is not possible to unequivocally distinguish an MGUS tumor cell from an MM tumor cell. However, two models based on clinical laboratory tests indicate that it is possible to stratify MGUS tumors into groups that have average rates of progression as low as 0.26% per year and as high as 12% per year. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21232653      PMCID: PMC3040450          DOI: 10.1053/j.seminhematol.2010.11.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  65 in total

1.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

2.  The significance of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Shaji Kumar
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

3.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

4.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

6.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 7.  Centrosomes and myeloma; aneuploidy and proliferation.

Authors:  Wee J Chng; Rafael Fonseca
Journal:  Environ Mol Mutagen       Date:  2009-10       Impact factor: 3.216

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 9.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

10.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Marco Ladetto; Michael Kuehl; Tiziana Palumbo; Daniela Drandi; Cristian Taccioli; Nicola Zanesi; Hansjuerg Alder; John P Hagan; Reinhold Munker; Stefano Volinia; Mario Boccadoro; Ramiro Garzon; Antonio Palumbo; Rami I Aqeilan; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

View more
  31 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Risk factors for monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Maira A Castaneda-Avila; Christine M Ulbricht; Mara Meyer Epstein
Journal:  Ann Hematol       Date:  2021-01-08       Impact factor: 3.673

Review 3.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors:  N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

5.  Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture.

Authors:  Denise K Walters; Diane F Jelinek
Journal:  J Histochem Cytochem       Date:  2019-12-19       Impact factor: 2.479

6.  Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Authors:  Adriana Zingone; Weixin Wang; Meghan Corrigan-Cummins; S Peter Wu; Ryan Plyler; Neha Korde; Mary Kwok; Elisabet E Manasanch; Nishant Tageja; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Mark Roschewski; Yong Zhang; Aldo M Roccaro; Irene M Ghobrial; Katherine R Calvo; Ola Landgren
Journal:  Cytokine       Date:  2014-07-17       Impact factor: 3.861

7.  Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.

Authors:  Philipp M Altrock; Jeremy Ferlic; Tobias Galla; Michael H Tomasson; Franziska Michor
Journal:  JCO Clin Cancer Inform       Date:  2018-12

Review 8.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

9.  [Multiple myeloma].

Authors:  K M Kortüm; M Engelhardt; L Rasche; S Knop; H Einsele
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

10.  [PET-CT for nuclear medicine diagnostics of multiple myeloma].

Authors:  A Dimitrakopoulou-Strauss
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.